The Effect of Vitamin D Repletion in Patients With Hepatocellular Carcinoma on the Orthotopic Liver Transplant List

• Status: Unknown status
• Trial end date: 2013-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the effect of two different doses of vitamin D3 (2000 IU vs. 4000 IU) on serum 25-hydroxyvitamin D (25OHD) levels in patients with hepatocellular carcinoma on the liver transplant list. The study will help determine the dose of vitamin D3 that is required for patients with liver cancer to reach a normal level of 25OHD in the blood.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Andrea Branch
• Treatments: Cholecalciferol; Ergocalciferols; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

• Adult patients (18 years and older)

• Diagnosis of hepatocellular carcinoma

• On the list awaiting liver transplantation

• Able to give informed consent

• Expected to receive care following liver transplantation at the Mount Sinai School of Medicine

• Any race/ethnicity/socioeconomic status

Exclusion Criteria:

• Pediatric patient (less than 18 years of age)

• Unable to give informed consent

• Untreated primary hyperparathyroidism (ICD9 codes 252.01XX and 252.00XX)

• Untreated hypercalcemia (serum calcium level > 11 mg/dl; ICD9 codes 275.42XX, 259.3XX, 252.00F)

• Pregnancy (will be determined by asking the patient and reviewing the medical record)